| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.23 | 6e-09 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.17 | 6e-06 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-05 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-05 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.36 | 0.0008 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | 0.13 | 0.001 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.001 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.16 | 0.002 |